CDER’s the latest proposal to withdraw the accelerated approval of Makena (HPC) was based upon a considerable randomized demo that unsuccessful to confirm the good thing about this drug to newborns or reduce the chance of PTB. In generating the decision to propose Makena’s withdrawal, CDER also reviewed effects from prior scientific tests of